SVB Securities analyst Jonathan Chang reiterated a Buy rating on Harpoon Therapeutics (HARP – Research Report) on November 14 and set a price target of $4.00. The company’s shares closed yesterday at $0.81.
Chang covers the Healthcare sector, focusing on stocks such as Bicycle Therapeutics, ImmunoGen, and Adaptimmune Therapeutics. According to TipRanks, Chang has an average return of -11.1% and a 32.42% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Harpoon Therapeutics with a $4.63 average price target.
Based on Harpoon Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $8.3 million and a GAAP net loss of $17.35 million. In comparison, last year the company earned a revenue of $5.84 million and had a GAAP net loss of $16.76 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company, which develops a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. It offers Tri-specific T cell Activating Construct (TriTACs) that focuses on the treatment of solid tumors and hematologic malignancies. The company founded by Patrick A. Baeuerle, Luke B. Evnin, and Jeanmarie Guenot on March 19, 2015 and is headquartered in South San Francisco, CA.
Read More on HARP:
- Harpoon Therapeutics reports Q3 EPS (35c), consensus (56c)
- Harpoon Therapeutics to Present Interim Results from Phase 1 Clinical Trial of T Cell Engager HPN217 at the 64th ASH Annual Meeting and Exposition
- Harpoon Therapeutics Appoints Luke Walker, M.D., as Chief Medical Officer
- Harpoon Therapeutics Appoints Lauren Silvernail to Board of Directors